FDA Red Tape Is Killing Small Medical Innovators

What does FDA review cost a small innovator?

Bringing a new medical device to market can cost a small company more than $300,000 in direct review expenses, consultant fees, and delayed revenue. The FDA's fiscal year 2024 budget reached $6.9 billion, yet the agency still moves at a pace better suited to multinational corporations than to garage startups. For a small business, an 18-month review cycle can consume the entire runway between a working prototype and bankruptcy. That is not patient protection. It is barrier construction.

The standard 510(k) pathway requires a company to show that its device is substantially equivalent to an existing product. For fiscal year 2025, the full user fee for a 510(k) submission sits at $22,745, with a reduced rate for qualified small businesses. The fee itself is not the killer. The killer is the preparation. Companies routinely spend $100,000 to $300,000 on consultants, testing, and quality systems just to file. Then they wait. FDA review times for 510(k) clearances average roughly 165 days, according to agency performance reports, and many stretch past a year.

Those delays have real consequences. A startup with six months of cash cannot absorb a 15-month review. It either sells early to a giant, gives up equity to venture firms, or dies. The device may be safer and cheaper than the incumbent product. Patients never find out. Washington calls this regulation. Startups call it a tax on hope.

Why big companies love the current system

Large medical device manufacturers employ teams of regulatory specialists who speak FDA as a first language. They file dozens of submissions each year, maintain quality systems the size of phone books, and can wait out delays that crush smaller rivals. Regulation that looks neutral on paper acts as a moat in practice. Big business can afford compliance. Small business cannot.

The medical technology sector includes giants such as Medtronic, Abbott, and Johnson and Johnson, each with market capitalizations in the hundreds of billions. These firms benefit when the cost of entry rises. Every dollar a startup must spend on paperwork is a dollar it cannot spend on engineering or clinical validation. Incumbents do not need to out-innovate newcomers. They only need to outlast them.

Congress created this dynamic through decades of statutory expansion. The Medical Device Amendments of 1976 gave the FDA authority over devices. Subsequent user fee acts added revenue but also layered on reporting requirements. Each rule seemed reasonable in isolation. Together they form a wall. Small companies hit it first.

What patients lose under the status quo

Americans spent $4.5 trillion on health care in 2022, about 17.3 percent of gross domestic product, according to the Centers for Medicare and Medicaid Services. Much of that spending reflects high prices for existing products rather than competition from better ones. When FDA delays keep new devices off the market, patients pay more for older technology. They also wait longer for innovations in diagnostics, monitoring, and surgical tools.

The COVID-19 pandemic showed what faster review can deliver. The FDA authorized emergency use for tests, ventilators, and remote monitoring tools in weeks rather than months. Some of those authorizations were flawed, and critics rightly note the need for safety standards. But the episode proved the agency can move when it chooses. The question is why it moves so slowly for routine submissions that carry far lower risk.

Patients with chronic conditions feel the lag most acutely. A better continuous glucose monitor, a more portable dialysis device, or a cheaper hearing aid may sit in regulatory limbo while users suffer with outdated options. The FDA's mission is to protect patients from unsafe products. It should not protect established companies from competition.

How Congress can fix medical device approvals

Lawmakers should start with a simple reform. Exempt low-risk devices from the full 510(k) process if they meet transparent safety criteria. The FDA already runs a breakthrough devices program that speeds review for truly novel technologies. Congress should expand that model, not shrink it. More devices deserve a fast track, not fewer.

User fees should also fall hardest on those who can pay. Small businesses employ about 61.7 million Americans, according to the Small Business Administration. They should receive larger fee waivers and dedicated review lanes. A startup with 10 employees should not compete for attention with a company that files 100 submissions a year.

Finally, Congress should require the FDA to publish binding review timelines. If the agency misses a deadline, the submission should receive an automatic administrative approval with post-market surveillance. That rule would force the FDA to prioritize and give startups a predictable calendar. Bureaucracies respond to incentives like every other institution.

Medical innovation built the modern American health system. Small companies drove much of it. If Washington keeps treating garage inventors like pharmaceutical conglomerates, the next breakthrough will never reach a patient. The fix is not deregulation for its own sake. The fix is proportionate, predictable regulation that protects safety without smothering the competition that lowers prices and saves lives.